Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145 in recurrent, metastatic, or persistent cervical carcinoma
2024-510634-41-00Phase 2Completed
- Sponsor
- Iovance Biotherapeutics
- Start
- Mar 2024
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 7
01
Overview
Phase 2, open-label trial of LN-145 in Cervical Cancer (CC) (5 cohorts), sponsored by Iovance Biotherapeutics. Started Mar 2024; status: completed.
02
Drugs
LN-145
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2024-510634-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510634-41-00.